Akebia Therapeutics Inc.stresses that it will be holding the reins on important aspects of developing vadadustat for anemia in patients with chronic kidney disease (CKD) – including pricing and reimbursement – after shifting course on its US plans in order to bring Otsuka Pharmaceutical Co. Ltd.on board in a 50-50 deal.
Otsuka committed at least $265m to partner with Akebia, including upfront fees and development capital, in a co-development and commercialization deal for vadadustat, a once-daily, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) stabilizer in Phase IIII for CKD-related anemia – a condition that affects some 1.8m people in the US. The agreement announced on Dec
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?